Tariq Musa sold $19K of GH

Tariq Musa sold 116 shares of Guardant Health, Inc. (GH) at $163.29 on 2026-07-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tariq Musa
Published Jul 16, 2026, 8:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 16, 2026, 9:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GH
Neutral
high confidence
Mentioned
$GH
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

The newest concrete fact is the specific sale details (116 shares at $163.29, total $18,941.64) and that it was executed under a pre-arranged Rule 10b5-1 plan.

02

Market read

Traders may note the planned insider selling, but there is no accompanying fundamental news in the text.

03

What to watch

The transaction size is small relative to typical institutional flows, and the filing does not disclose any change in business outlook, only the sale mechanics.

Relevance 2/10Novelty 3/10Timing: Filed on 2026-07-16, after-hours SEC EDGAR timestamp.

Background

The article is a SEC Form 4 insider transaction disclosure for Guardant Health, Inc., reported by director Tariq Musa.

Company-level read

Ticker impact

$GHNeutralHigh confidence
Context

Guardant Health director Tariq Musa filed a Form 4 open-market sale of 116 shares at $163.29 on 2026-07-16 under a 10b5-1 plan.

Expected impact

Likely negligible immediate price impact; any effect is more sentiment-level than fundamental.

Evidence & confidence

The filing is an insider transaction (not an earnings, guidance, deal, or regulatory event) and the article specifies a pre-arranged 10b5-1 plan, which typically reduces interpretive weight.

Market effects

No clear read-through to biotech/diagnostics sector fundamentals from a small, planned insider sale.

None indicated.

None indicated.

Counterpoint

Even planned 10b5-1 sales can coincide with insider expectations of near-term risk, but the article provides no additional company-specific catalyst.

Key entities

  • Guardant Health, Inc.

    US-listed company subject of the Form 4 insider transaction disclosure.

  • Tariq Musa

    Director of Guardant Health who reported an open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GHHighAI 8/10

Why is Guardant Health stock climbing today?

Guardant Health (GH) stock rose 2.5% in pre-market trading after pricing a $500M offering of 0% convertible notes due 2032, with a 35% premium conversion price. The company plans to use proceeds to repurchase $395.2M of existing convertible notes due 2027, optimizing its balance sheet. The move came amid broader market headwinds for growth and tech names.